Tresiba Legal and Patent Challenges

FDA Approval History: A Two-Cycle Review

Tresiba's path to FDA approval was not straightforward. Novo Nordisk submitted its original new drug application in 2012, but the FDA issued a complete response letter (CRL) in November 2013 requesting additional cardiovascular safety data before it would approve the drug. That CRL forced Novo Nordisk to design and execute the DEVOTE trial, adding roughly two years to the U.S. Launch timeline.

The 2013 Complete Response Letter

The CRL reflected FDA caution after lessons learned from the rosiglitazone cardiovascular controversy. The agency's 2008 guidance for diabetes drugs set the expectation that sponsors demonstrate their products do not carry unacceptable cardiovascular risk [1]. Insulin degludec had already been approved by the European Medicines Agency (EMA) in January 2013, making the U.S. Delay notable. The EMA's European Public Assessment Report (EPAR) cited favorable glycemic control data from the BEGIN trial program but did not require a dedicated cardiovascular outcomes trial at the time of approval.

The 2015 Approval

On September 25, 2015, the FDA approved Tresiba based on the existing clinical data package while the DEVOTE trial was still ongoing. The agency determined that the interim cardiovascular data were sufficient to support approval, with the final DEVOTE results to follow as a post-marketing commitment [2]. The Drugs@FDA entry for NDA 203314 confirms the approval for both U-100 and U-200 concentrations in the FlexTouch pen.

The DEVOTE Trial and Label Update

The DEVOTE trial (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Subjects with Type 2 Diabetes at High Risk of Cardiovascular Events) randomized 7,637 patients with type 2 diabetes and high cardiovascular risk to insulin degludec or insulin glargine U-100. Published in the New England Journal of Medicine in 2017, DEVOTE demonstrated that insulin degludec was noninferior to insulin glargine for major adverse cardiovascular events (MACE), with a hazard ratio of 0.91 (95% CI, 0.78 to 1.06) [3]. The rate of severe hypoglycemia was significantly lower with degludec (4.9% vs. 6.6%, P<0.001 for superiority).

These results led to a supplemental label update. The Tresiba prescribing information now includes data from DEVOTE showing the reduced severe hypoglycemia rate, which became a differentiating clinical claim against insulin glargine.

Patent Field and Orange Book Listings

Novo Nordisk built a substantial patent estate around Tresiba that covers the insulin degludec molecule itself, specific pharmaceutical formulations, the zinc-phenol stabilization system, and the FlexTouch pen device. Understanding this patent portfolio is necessary for any manufacturer considering a biosimilar or interchangeable filing.

Key Patent Categories

The patents listed in the FDA's Orange Book for Tresiba fall into three broad groups:

1. Composition-of-matter patents covering the acylated insulin analog with a hexadecandioyl fatty acid side chain. These are the most difficult to design around.
2. Formulation patents covering the specific combination of insulin degludec with phenol, m-cresol, zinc, and other excipients that produce the ultra-long pharmacokinetic profile.
3. Device patents covering the FlexTouch pen injector, including the dose-setting mechanism and dose-delivery confirmation window.

Expiration Timeline

The earliest Orange Book listed patents began expiring in the mid-2020s, with several formulation and device patents extending to 2029 and beyond. Novo Nordisk also holds pediatric exclusivity extensions on certain patents, which add six months to their expiration dates. The exact expiration schedule depends on patent term adjustments granted by the U.S. Patent and Trademark Office (USPTO) to compensate for regulatory delays during the approval process.

The Biologic Transition: NDA to BLA

A major regulatory shift occurred on March 23, 2020, when insulin products in the United States transitioned from the drug approval pathway (NDA, regulated under the Federal Food, Drug, and Cosmetic Act) to the biologic approval pathway (BLA, regulated under the Public Health Service Act). This change, mandated by the Biologics Price Competition and Innovation Act of 2009 (BPCIA), has direct implications for Tresiba's competitive field.

What Changed for Tresiba

Under the NDA pathway, generic competitors would have filed Abbreviated New Drug Applications (ANDAs) and relied on Hatch-Waxman Act provisions for patent challenges. Under the BLA pathway, biosimilar applicants file under section 351(k) of the PHS Act and must manage the BPCIA's "patent dance," a structured information exchange process between the biosimilar applicant and the reference product sponsor [4].

The patent dance creates a different litigation dynamic. The reference product sponsor (Novo Nordisk) must provide its patent list within 60 days of receiving the biosimilar application. The applicant then identifies which patents it believes are invalid, unenforceable, or not infringed. This back-and-forth narrows the patents that will be litigated, potentially reducing the scope of patent disputes compared to the Hatch-Waxman paragraph IV certification process.

Impact on Biosimilar Development

The biologic transition also changed the data exclusivity period. Under the BPCIA, reference biologics receive 12 years of data exclusivity from the date of first licensure and 4 years of exclusivity before a biosimilar application can even be submitted [5]. For insulin products that were already approved as drugs before March 2020, the FDA applied the deemed-BLA transition date as the reference point. The practical effect: biosimilar insulin degludec applications could not reference Tresiba's clinical data until the exclusivity periods lapsed based on the deemed-BLA date.

Legal Challenges and Patent Litigation

Novo Nordisk has actively defended its Tresiba patent estate through litigation. Multiple manufacturers have signaled interest in bringing biosimilar or interchangeable insulin degludec products to market, and several have filed or are expected to file 351(k) applications.

Paragraph IV-Era Challenges

Before the biologic transition, at least one manufacturer filed an ANDA with paragraph IV certifications against Tresiba's Orange Book listed patents. These filings triggered 30-month stays of FDA approval, during which Novo Nordisk pursued infringement litigation in federal district court. The outcomes of these early challenges set precedent for how the formulation patents would be interpreted.

Post-Transition BPCIA Litigation

After March 2020, the litigation framework shifted to the BPCIA patent dance. Public records indicate that Novo Nordisk has engaged in patent dance negotiations with biosimilar applicants. The key patents under dispute tend to be the formulation claims, because the composition-of-matter patents for the insulin degludec molecule face stronger validity arguments based on prior art in the acylated insulin space.

International Patent Disputes

Tresiba's patent challenges are not limited to the United States. In Europe, Novo Nordisk's supplementary protection certificates (SPCs) for insulin degludec have been challenged in multiple jurisdictions. The EMA's approval in 2013 triggered SPC filings that extend market exclusivity in EU member states, and generic/biosimilar manufacturers have mounted validity challenges in national patent offices and courts in Germany, the United Kingdom (pre-Brexit), and the Netherlands.

Safety and Labeling: Post-Market Regulatory Actions

Tresiba's label has undergone several revisions since the 2015 approval, reflecting both new clinical data and routine pharmacovigilance findings.

Hypoglycemia Warnings

The current Tresiba prescribing information carries the standard boxed warning-free format for basal insulins but includes detailed warnings about hypoglycemia, particularly in the context of dose adjustments, renal impairment, and hepatic impairment. The DEVOTE data showing lower rates of severe hypoglycemia compared to insulin glargine (4.9% vs. 6.6%, P<0.001) were added via a supplemental labeling update [3].

Cardiovascular Safety Language

The labeling now includes a clinical studies section describing the DEVOTE results. The hazard ratio of 0.91 (95% CI, 0.78 to 1.06) for MACE confirmed cardiovascular noninferiority [3]. This section satisfies the FDA's post-marketing commitment that was a condition of the 2015 approval.

FDA Sentinel System Monitoring

The FDA Sentinel System, which uses distributed electronic health record data from over 100 million patients, has been used for ongoing post-market surveillance of insulin degludec. Sentinel queries have examined real-world rates of severe hypoglycemia, diabetic ketoacidosis (DKA), and cardiovascular events. No new safety signals from Sentinel have triggered formal regulatory action against Tresiba as of early 2026.

Medication Error Reports

One area of post-market focus has been medication errors related to the U-200 concentration. The FDA received reports of dosing confusion between U-100 and U-200 formulations. Novo Nordisk addressed this through labeling clarifications and design modifications to the pen labeling. The FDA's MedWatch system continues to track these reports.

Pricing Litigation and Policy Pressure

Beyond patent disputes, Tresiba has been caught up in broader legal and policy challenges related to insulin pricing in the United States.

State Attorney General Actions

Multiple state attorneys general have investigated or filed lawsuits against insulin manufacturers, including Novo Nordisk, alleging anticompetitive pricing practices. These cases typically focus on the relationship between list prices, pharmacy benefit manager (PBM) rebates, and patient out-of-pocket costs. Tresiba's list price trajectory, which increased significantly between 2016 and 2022, has been cited in several of these complaints [6].

The Inflation Reduction Act

The Inflation Reduction Act of 2022 capped out-of-pocket insulin costs at $35 per month for Medicare Part D beneficiaries, effective January 2023. While this legislation did not directly address patent issues, it changed the economic calculus for biosimilar developers. A $35 cap reduces the price advantage that a biosimilar could offer to patients, potentially affecting the commercial incentive to challenge Tresiba's patents [7].

Novo Nordisk's Price Reductions

In response to political pressure, Novo Nordisk announced in March 2023 that it would reduce the list price of Tresiba by up to 65%. This voluntary reduction may influence the competitive dynamics around biosimilar entry, as the reduced price narrows the margin available to biosimilar competitors.

What Comes Next: Biosimilar Insulin Degludec

The path to biosimilar insulin degludec depends on the resolution of ongoing patent litigation, the completion of biosimilarity studies, and FDA review timelines.

Clinical Requirements for Biosimilar Approval

A 351(k) biosimilar applicant must demonstrate that its product is highly similar to Tresiba with no clinically meaningful differences in safety, purity, or potency. This typically requires analytical characterization, animal studies, and at least one clinical pharmacokinetic/pharmacodynamic (PK/PD) study. For an interchangeability designation, the applicant must also conduct a switching study [8].

Expected Timeline

Based on patent expiration dates and the typical BPCIA litigation timeline, the earliest biosimilar insulin degludec products could reach the U.S. Market in the late 2020s to early 2030s. The exact date depends on whether any settlement agreements include authorized generic launches before full patent expiry.

As Dr. Jeremy Greene of Johns Hopkins University School of Medicine has noted regarding insulin biosimilar pathways: "The transition of insulins to the biologic pathway created a more rigorous but also more predictable framework for biosimilar competition" [9].

The Endocrine Society's 2024 position statement on insulin access stated: "Biosimilar competition remains one of the most effective long-term strategies for reducing insulin costs, but patent thickets and regulatory complexity continue to delay market entry" [10].

Clinicians prescribing Tresiba should monitor the FDA's Purple Book for biosimilar and interchangeable listings and plan for formulary changes as biosimilar insulin degludec products receive approval. Patients currently stable on Tresiba U-100 or U-200 should discuss with their prescriber before switching to any biosimilar, as interchangeability designation (which permits pharmacy-level substitution) requires a higher evidentiary bar than biosimilarity alone [8].